Barbara A. Konkle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Barbara A. Konkle has a total of 894 co-authors. Here are the top co-authors by number of shared publications:
- Jill M. Johnsen
University of Washington, Seattle, Washington, United States
7 shared publications - Glenn F. Pierce
World Federation of Hemophilia
5 shared publications - Steven W. Pipe
University of Michigan
5 shared publications - Alexander G. Bick
Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, USA
4 shared publications - Alfonso Iorio
Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Canada
4 shared publications - Barry I. Freedman
Wake Forest University School of Medicine
4 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (sup1) , 63-79
Research agenda and related workforce requirements inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research Collaborative
1. 1.1. The National Research Blueprint (NRB) proposes a change in how inheritable bleeding disorders (BD) research in the U.S. is conducted and who it engages: a Bleeding Disorders Research Collab...
- 31 July 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (sup1) , 63-79
Open AccessResearch agenda and related workforce requirements inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research Collaborative
1. 1.1. The National Research Blueprint (NRB) proposes a change in how inheritable bleeding disorders (BD) research in the U.S. is conducted and who it engages: a Bleeding Disorders Research Collab...
- Open Access
- 10 July 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (3)
Safety and Hematologic Impact of High-Dose N-Acetylcysteine Infusion in Sickle Cell Disease
- 10 July 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (3)
Open AccessSafety and Hematologic Impact of High-Dose N-Acetylcysteine Infusion in Sickle Cell Disease
- Top Cited PapersOpen Access
- 13 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3409-3417
A revised classification of FVIII concentrates: rationale and novel metrics
Factor VIII (FVIII) replacement remains central to the management of hemophilia A. Extended half-life (EHL)–FVIII concentrates, developed through Fc-fusion or PEGylation, extend terminal half-life and overall exposure area under the curve (AUC) by ∼30% compared with standard half-life (SHL) products but remain limited by the von Willebrand factor (VWF)–imposed half-life ceiling. A newly engineered high-sustained-activity/ultralong half-life FVIII (HSA/UL-FVIII) eliminates VWF binding through multiple structural modifications, achieving a fourfold longer half-life, a sixfold greater AUC than SHL-FVIII, and FVIII activity within the nonhemophilia range for several days following once-weekly dosing. Using population pharmacokinetic (PK) modeling, we simulated single-dose and steady-state FVIII activity-time profiles in 1000 virtual patients treated with SHL-, EHL-, or HSA/UL-FVIII. Time spent and area above clinically relevant FVIII thresholds clearly differentiated HSA/UL-FVIII from EHL products. These data support updating FVIII product classification and highlight the value of new PK-based metrics, including time-above-threshold and segmented AUC, in evaluating next-generation FVIII therapies.
- 13 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3409-3417
Top Cited PapersOpen AccessA revised classification of FVIII concentrates: rationale and novel metrics
Factor VIII (FVIII) replacement remains central to the management of hemophilia A. Extended half-life (EHL)–FVIII concentrates, developed through Fc-fusion or PEGylation, extend terminal half-life and overall exposure area under the curve (AUC) by ∼30% compared with standard half-life (SHL) products but remain limited by the von Willebrand factor (VWF)–imposed half-life ceiling. A newly engineered high-sustained-activity/ultralong half-life FVIII (HSA/UL-FVIII) eliminates VWF binding through multiple structural modifications, achieving a fourfold longer half-life, a sixfold greater AUC than SHL-FVIII, and FVIII activity within the nonhemophilia range for several days following once-weekly dosing. Using population pharmacokinetic (PK) modeling, we simulated single-dose and steady-state FVIII activity-time profiles in 1000 virtual patients treated with SHL-, EHL-, or HSA/UL-FVIII. Time spent and area above clinically relevant FVIII thresholds clearly differentiated HSA/UL-FVIII from EHL products. These data support updating FVIII product classification and highlight the value of new PK-based metrics, including time-above-threshold and segmented AUC, in evaluating next-generation FVIII therapies.
- Open Access
- 20 January 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis
Background: Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy. In the phase III XTEND-1 (NCT04161495) study, once-weekly efanesoctocog alfa prophylaxis (50 IU/kg) was well-tolerated and achieved high-sustained factor levels in the normal to near-normal range (>40%) for most of the week. Objective: To report outcomes in previously treated participants with severe haemophilia A aged ⩾12 years from an observational study who switched to efanesoctocog alfa prophylaxis during XTEND-1. Design: Paired assessment of participants from an observational study who enrolled in the phase III XTEND-1 study. Methods: Seventy-eight participants switched from marketed standard half-life (SHL) or extended half-life (EHL) FVIII prophylaxis to once-weekly efanesoctocog alfa prophylaxis (50 IU/kg). Endpoints included annualized bleed rates (ABRs), treatment of bleeding episodes, injection frequency and FVIII consumption. Results: Pre-study, 44 (56%) and 34 (44%) participants received SHL FVIII or EHL FVIII prophylaxis, respectively. In the overall population, a significant reduction in ABR from 2.96 to 0.69 ( p < 0.0001) was observed following the switch to efanesoctocog alfa prophylaxis as well as reductions in spontaneous, traumatic, joint and spontaneous joint ABRs ( p < 0.0001). Significant reductions in mean weekly injection frequency were observed, from 2.8 to 1.0 in the SHL FVIII cohort ( p < 0.0001) and from 1.8 to 1.0 in the EHL FVIII cohort ( p < 0.0001). Mean annualized factor consumption reduced by 47% in the SHL FVIII cohort and 30% in the EHL FVIII cohort. Conclusion: Collectively, the results of this post hoc analysis demonstrate the benefits of once-weekly efanesoctocog alfa prophylaxis over SHL or EHL FVIII prophylaxis on bleed rates, injection frequency and consumption. Trial registration: Observational study: 242HA201/OBS16221; XTEND-1: NCT04161495 ( https://clinicaltrials.gov/study/NCT04161495 ).
- 20 January 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessOutcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis
Background: Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy. In the phase III XTEND-1 (NCT04161495) study, once-weekly efanesoctocog alfa prophylaxis (50 IU/kg) was well-tolerated and achieved high-sustained factor levels in the normal to near-normal range (>40%) for most of the week. Objective: To report outcomes in previously treated participants with severe haemophilia A aged ⩾12 years from an observational study who switched to efanesoctocog alfa prophylaxis during XTEND-1. Design: Paired assessment of participants from an observational study who enrolled in the phase III XTEND-1 study. Methods: Seventy-eight participants switched from marketed standard half-life (SHL) or extended half-life (EHL) FVIII prophylaxis to once-weekly efanesoctocog alfa prophylaxis (50 IU/kg). Endpoints included annualized bleed rates (ABRs), treatment of bleeding episodes, injection frequency and FVIII consumption. Results: Pre-study, 44 (56%) and 34 (44%) participants received SHL FVIII or EHL FVIII prophylaxis, respectively. In the overall population, a significant reduction in ABR from 2.96 to 0.69 ( p < 0.0001) was observed following the switch to efanesoctocog alfa prophylaxis as well as reductions in spontaneous, traumatic, joint and spontaneous joint ABRs ( p < 0.0001). Significant reductions in mean weekly injection frequency were observed, from 2.8 to 1.0 in the SHL FVIII cohort ( p < 0.0001) and from 1.8 to 1.0 in the EHL FVIII cohort ( p < 0.0001). Mean annualized factor consumption reduced by 47% in the SHL FVIII cohort and 30% in the EHL FVIII cohort. Conclusion: Collectively, the results of this post hoc analysis demonstrate the benefits of once-weekly efanesoctocog alfa prophylaxis over SHL or EHL FVIII prophylaxis on bleed rates, injection frequency and consumption. Trial registration: Observational study: 242HA201/OBS16221; XTEND-1: NCT04161495 ( https://clinicaltrials.gov/study/NCT04161495 ).
- 25 October 2025
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 20-54
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025
- 25 October 2025
- Published by Wiley in Haemophilia
- Vol. 32 (1) , 20-54
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025
- 16 September 2025
- Published by Wiley in Haemophilia
- Vol. 31 (6) , 1349-1351
The Critical Need to Consolidate All Gene Therapy Data in Haemophilia
- 16 September 2025
- Published by Wiley in Haemophilia
- Vol. 31 (6) , 1349-1351
The Critical Need to Consolidate All Gene Therapy Data in Haemophilia
- Open Access
- 14 March 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (7) , 2086-2094
Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance
- 14 March 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (7) , 2086-2094
Open AccessCorticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance
- 3 April 2024
- Published by Wiley in Haemophilia
- Vol. 30 (S3) , 21-28
The importance and evolution of bleeding disorder registries
Registries are excellent sources of data to address questions that are typically not evaluated in randomized clinical trials, including natural history, disease prevalence, treatment approaches and adverse events, and models of care. Global and regional registries can provide data to identify differences in outcomes and in haemophilia care between countries, economic settings, and regions, while facilitating research and data sharing. In this manuscript, we highlight five bleeding disorder registries: Country registries from Australia and China, Paediatric Network on Haemophilia Management (PedNet) data on children who have received emicizumab, data from the European Haemophilia Safety Surveillance (EUHASS) system, and data on women and girls with haemophilia from the World Federation of Haemophilia (WFH) registries. Data from these and other bleeding disorder registries have been and will continue to be used to advance patient care, understand treatment patterns and adverse reactions, and identify areas of increased need and focus.
- 3 April 2024
- Published by Wiley in Haemophilia
- Vol. 30 (S3) , 21-28
The importance and evolution of bleeding disorder registries
Registries are excellent sources of data to address questions that are typically not evaluated in randomized clinical trials, including natural history, disease prevalence, treatment approaches and adverse events, and models of care. Global and regional registries can provide data to identify differences in outcomes and in haemophilia care between countries, economic settings, and regions, while facilitating research and data sharing. In this manuscript, we highlight five bleeding disorder registries: Country registries from Australia and China, Paediatric Network on Haemophilia Management (PedNet) data on children who have received emicizumab, data from the European Haemophilia Safety Surveillance (EUHASS) system, and data on women and girls with haemophilia from the World Federation of Haemophilia (WFH) registries. Data from these and other bleeding disorder registries have been and will continue to be used to advance patient care, understand treatment patterns and adverse reactions, and identify areas of increased need and focus.
- Top Cited PapersOpen Access
- 29 February 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (9) , 796-806
Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
Patients with hemophilia A require exogenous factor VIII (FVIII) or nonfactor hemostatic agents to prevent spontaneous bleeding events. Adeno-associated virus (AAV) vector–based gene therapy is under clinical investigation to enable endogenous FVIII production. Giroctocogene fitelparvovec is a recombinant AAV serotype 6 vector containing the coding sequence for the B-domain–deleted human F8 gene. In the ongoing phase 1/2, dose-ranging Alta study, 4 sequential cohorts of male participants with severe hemophilia A received a single IV dose of giroctocogene fitelparvovec. The primary end points are safety and changes in circulating FVIII activity. Interim results up to 214 weeks after treatment for all participants are presented. Eleven participants were dosed. Increases in alanine and aspartate aminotransferases were the most common treatment-related adverse events (AEs), which resolved with corticosteroid administration. Two treatment-related serious AEs (hypotension and pyrexia) were reported in 1 participant within 6 hours of infusion and resolved within 24 hours after infusion. At the highest dose level (3 × 1013 vg/kg; n = 5), the mean circulating FVIII activity level at week 52 was 42.6% (range, 7.8%-122.3%), and at week 104 it was 25.4% (range, 0.9%-71.6%) based on a chromogenic assay. No liver masses, thrombotic events, or confirmed inhibitors were detected in any participant. These interim 104-week data suggest that giroctocogene fitelparvovec is generally well tolerated with appropriate clinical management and has the potential to provide clinically meaningful FVIII activity levels, as indicated by the low rate of bleeding events in the highest dose cohort. This trial was registered at www.clinicaltrials.gov as #NCT03061201.
- 29 February 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (9) , 796-806
Top Cited PapersOpen AccessGiroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study
Patients with hemophilia A require exogenous factor VIII (FVIII) or nonfactor hemostatic agents to prevent spontaneous bleeding events. Adeno-associated virus (AAV) vector–based gene therapy is under clinical investigation to enable endogenous FVIII production. Giroctocogene fitelparvovec is a recombinant AAV serotype 6 vector containing the coding sequence for the B-domain–deleted human F8 gene. In the ongoing phase 1/2, dose-ranging Alta study, 4 sequential cohorts of male participants with severe hemophilia A received a single IV dose of giroctocogene fitelparvovec. The primary end points are safety and changes in circulating FVIII activity. Interim results up to 214 weeks after treatment for all participants are presented. Eleven participants were dosed. Increases in alanine and aspartate aminotransferases were the most common treatment-related adverse events (AEs), which resolved with corticosteroid administration. Two treatment-related serious AEs (hypotension and pyrexia) were reported in 1 participant within 6 hours of infusion and resolved within 24 hours after infusion. At the highest dose level (3 × 1013 vg/kg; n = 5), the mean circulating FVIII activity level at week 52 was 42.6% (range, 7.8%-122.3%), and at week 104 it was 25.4% (range, 0.9%-71.6%) based on a chromogenic assay. No liver masses, thrombotic events, or confirmed inhibitors were detected in any participant. These interim 104-week data suggest that giroctocogene fitelparvovec is generally well tolerated with appropriate clinical management and has the potential to provide clinically meaningful FVIII activity levels, as indicated by the low rate of bleeding events in the highest dose cohort. This trial was registered at www.clinicaltrials.gov as #NCT03061201.
- Open Access
- 14 February 2024
- Published by Springer Nature in Gene Therapy
- Vol. 31 (5-6) , 273-284
Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia
Adeno-associated virus (AAV) based gene therapy has demonstrated effective disease control in hemophilia. However, pre-existing immunity from wild-type AAV exposure impacts gene therapy eligibility. The aim of this multicenter epidemiologic study was to determine the prevalence and persistence of preexisting immunity against AAV2, AAV5, and AAV8, in adult participants with hemophilia A or B. Blood samples were collected at baseline and annually for ≤3 years at trial sites in Austria, France, Germany, Italy, Spain, and the United States. At baseline, AAV8, AAV2, and AAV5 neutralizing antibodies (NAbs) were present in 46.9%, 53.1%, and 53.4% of participants, respectively; these values remained stable at Years 1 and 2. Co-prevalence of NAbs to at least two serotypes and all three serotypes was present at baseline for ~40% and 38.2% of participants, respectively. For each serotype, ~10% of participants who tested negative for NAbs at baseline were seropositive at Year 1. At baseline, 38.3% of participants had detectable cell mediated immunity by ELISpot, although no correlations were observed with the humoral response. In conclusion, participants with hemophilia may have significant preexisting immunity to AAV capsids. Insights from this study may assist in understanding capsid-based immunity trends in participants considering AAV vector-based gene therapy.
- 14 February 2024
- Published by Springer Nature in Gene Therapy
- Vol. 31 (5-6) , 273-284
Open AccessMulticenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia
Adeno-associated virus (AAV) based gene therapy has demonstrated effective disease control in hemophilia. However, pre-existing immunity from wild-type AAV exposure impacts gene therapy eligibility. The aim of this multicenter epidemiologic study was to determine the prevalence and persistence of preexisting immunity against AAV2, AAV5, and AAV8, in adult participants with hemophilia A or B. Blood samples were collected at baseline and annually for ≤3 years at trial sites in Austria, France, Germany, Italy, Spain, and the United States. At baseline, AAV8, AAV2, and AAV5 neutralizing antibodies (NAbs) were present in 46.9%, 53.1%, and 53.4% of participants, respectively; these values remained stable at Years 1 and 2. Co-prevalence of NAbs to at least two serotypes and all three serotypes was present at baseline for ~40% and 38.2% of participants, respectively. For each serotype, ~10% of participants who tested negative for NAbs at baseline were seropositive at Year 1. At baseline, 38.3% of participants had detectable cell mediated immunity by ELISpot, although no correlations were observed with the humoral response. In conclusion, participants with hemophilia may have significant preexisting immunity to AAV capsids. Insights from this study may assist in understanding capsid-based immunity trends in participants considering AAV vector-based gene therapy.